search
Back to results

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

Primary Purpose

Geographic Atrophy

Status
Active
Phase
Phase 2
Locations
International
Study Type
Interventional
Intervention
Danicopan
Placebo
Sponsored by
Alexion
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Geographic Atrophy focused on measuring Geographic Atrophy, GA, Danicopan, ALXN2040, Complement Inhibition, AMD

Eligibility Criteria

60 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Key Inclusion Criteria:

  • Vaccination for Neisseria meningitidis.
  • Capable of giving signed informed consent.
  • Presentation of GA secondary to AMD in at least 1 eye
  • The entire GA lesion must be > 1 μm outside of the foveal center

Key Exclusion Criteria:

  • GA in the study eye due to cause other than AMD.
  • Have previously received intravitreal anti-vascular endothelial growth factor injections in study eye for intraocular vascular disease.
  • Have previously received any stem cell/gene therapy for any ophthalmological condition in either eye.
  • Previous participation in interventional clinical studies for any ophthalmic indications in the study eye regardless of route of administration within the last 3 months or 5 half-lives of the investigational product (whichever is longer).
  • Presence of active ocular diseases in the study eye that in the opinion of the Investigator compromises or confounds visual function or interferes with study assessments.
  • Known or suspected complement deficiency.
  • History or presence of any medical or psychological condition that, in the opinion of the Principal Investigator, would make the patient inappropriate for the study.
  • Hypersensitivity to fluorescein sodium for injection, the investigational drug (danicopan) or any of its excipients.

Note: Additional inclusion/exclusion criteria may apply, per protocol.

Sites / Locations

  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site
  • Clinical Study Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Placebo Comparator

Arm Label

Danicopan: 100 mg

Danicopan: 200 mg

Danicopan: 400 mg

Placebo

Arm Description

Participants will receive danicopan 100 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.

Participants will receive danicopan 200 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.

Participants will receive danicopan 400 mg qd during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.

Participants will receive matching placebo and will be re-randomized to one of the active treatment groups at Week 52, or to the optimal dose, if already identified.

Outcomes

Primary Outcome Measures

Change From Baseline To Week 52 In The Square Root (sqrt) Of Total GA Lesion Area In The Study Eye As Measured By Fundus Autofluorescence (FAF)

Secondary Outcome Measures

Change From Baseline To Week 104 In The Sqrt Of The Total GA Lesion Area In The Study Eye As Measured By FAF
Change From Baseline To Week 52 And Week 104 In The Total GA Lesion Area In The Study Eye As Measured By FAF
Change From Baseline To Week 52 And Week 104 In Monocular Best-corrected Visual Acuity (BCVA) Scores In The Study Eye As Assessed By The Early Treatment Diabetic Retinopathy Study (ETDRS) Chart
Change From Baseline To Week 52 And Week 104 In Monocular Low Luminance Visual Acuity (LLVA) Scores In The Study Eye As Assessed By The ETDRS Chart
Change From Baseline To Week 52 And Week 104 In Low Luminance Deficit (BCVA-LLVA) In The Study Eye
Change From Baseline To Week 52 And Week 104 In Monocular Reading Speeds In The Study Eye As Assessed By Minnesota Low Vision Reading Test (MNRead) Acuity Charts Or Radner Reading Charts
Plasma Concentration Of Danicopan Over Time
PD Biomarkers, Ex Vivo Serum Alternative Pathway Activity, And Plasma Bb Concentration Over Time
Change From Baseline To Week 52 and Week 104 in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) scores
Incidence Of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), And Ocular TEAEs, SAEs, And Clinical Laboratory Abnormalities, And Events Leading To Discontinuation Of Study Drug Throughout The Study

Full Information

First Posted
August 19, 2021
Last Updated
July 10, 2023
Sponsor
Alexion
search

1. Study Identification

Unique Protocol Identification Number
NCT05019521
Brief Title
A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration
Official Title
A Phase 2, Double-Masked, Placebo-Controlled, Dose Range Finding Study of Danicopan (ALXN2040) in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
August 20, 2021 (Actual)
Primary Completion Date
July 1, 2024 (Anticipated)
Study Completion Date
August 5, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Alexion

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a dose finding study designed to evaluate the efficacy, safety, and pharmacokinetics of danicopan in participants with GA secondary to AMD. The study consists of a Screening Period of up to 6 weeks, a 104-week masked Treatment Period, followed by a 30-day Follow-up after the last dose. This study will have 4 treatments arms: 100 milligrams (mg) twice daily (bid), 200 mg bid, 400 mg once daily (qd), and matching placebo.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Geographic Atrophy
Keywords
Geographic Atrophy, GA, Danicopan, ALXN2040, Complement Inhibition, AMD

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Masking Description
Masking of treatment allocation will be observed until Week 104.
Allocation
Randomized
Enrollment
365 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Danicopan: 100 mg
Arm Type
Experimental
Arm Description
Participants will receive danicopan 100 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
Arm Title
Danicopan: 200 mg
Arm Type
Experimental
Arm Description
Participants will receive danicopan 200 mg bid during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
Arm Title
Danicopan: 400 mg
Arm Type
Experimental
Arm Description
Participants will receive danicopan 400 mg qd during the masked Treatment Period. Once the optimal dose is identified, participants who have at least 52 weeks of treatment will be switched to the optimal dose for the remainder of the study.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive matching placebo and will be re-randomized to one of the active treatment groups at Week 52, or to the optimal dose, if already identified.
Intervention Type
Drug
Intervention Name(s)
Danicopan
Other Intervention Name(s)
ALXN2040
Intervention Description
Oral tablet.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Oral tablet.
Primary Outcome Measure Information:
Title
Change From Baseline To Week 52 In The Square Root (sqrt) Of Total GA Lesion Area In The Study Eye As Measured By Fundus Autofluorescence (FAF)
Time Frame
Baseline, Week 52
Secondary Outcome Measure Information:
Title
Change From Baseline To Week 104 In The Sqrt Of The Total GA Lesion Area In The Study Eye As Measured By FAF
Time Frame
Baseline, Week 104
Title
Change From Baseline To Week 52 And Week 104 In The Total GA Lesion Area In The Study Eye As Measured By FAF
Time Frame
Baseline, Week 52 and Week 104
Title
Change From Baseline To Week 52 And Week 104 In Monocular Best-corrected Visual Acuity (BCVA) Scores In The Study Eye As Assessed By The Early Treatment Diabetic Retinopathy Study (ETDRS) Chart
Time Frame
Baseline, Week 52 and Week 104
Title
Change From Baseline To Week 52 And Week 104 In Monocular Low Luminance Visual Acuity (LLVA) Scores In The Study Eye As Assessed By The ETDRS Chart
Time Frame
Baseline, Week 52 and Week 104
Title
Change From Baseline To Week 52 And Week 104 In Low Luminance Deficit (BCVA-LLVA) In The Study Eye
Time Frame
Baseline, Week 52 and Week 104
Title
Change From Baseline To Week 52 And Week 104 In Monocular Reading Speeds In The Study Eye As Assessed By Minnesota Low Vision Reading Test (MNRead) Acuity Charts Or Radner Reading Charts
Time Frame
Baseline, Week 52 and Week 104
Title
Plasma Concentration Of Danicopan Over Time
Time Frame
Up to 4 hours postdose
Title
PD Biomarkers, Ex Vivo Serum Alternative Pathway Activity, And Plasma Bb Concentration Over Time
Time Frame
Up to 4 hours postdose
Title
Change From Baseline To Week 52 and Week 104 in National Eye Institute Visual Function Questionnaire (NEI VFQ-25) scores
Time Frame
Baseline, Week 52 and Week 104
Title
Incidence Of Treatment-emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), And Ocular TEAEs, SAEs, And Clinical Laboratory Abnormalities, And Events Leading To Discontinuation Of Study Drug Throughout The Study
Time Frame
Day 1 through Week 104

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Key Inclusion Criteria: Vaccination for Neisseria meningitidis. Capable of giving signed informed consent. Presentation of GA secondary to AMD in at least 1 eye The entire GA lesion must be > 1 μm outside of the foveal center Key Exclusion Criteria: GA in the study eye due to cause other than AMD. Have previously received intravitreal anti-vascular endothelial growth factor injections in study eye for intraocular vascular disease. Have previously received any stem cell/gene therapy for any ophthalmological condition in either eye. Use of any investigational medicinal product (ie, participation in interventional clinical studies for any ophthalmic indications) or use of any regulatory approved treatment for GA in the study eye regardless of route of administration within the last 3 months or 5 half-lives of the last dose of the investigational or commercial product (whichever is longer). Presence of active ocular diseases in the study eye that in the opinion of the Investigator compromises or confounds visual function or interferes with study assessments. Known or suspected complement deficiency. History or presence of any medical or psychological condition that, in the opinion of the Principal Investigator, would make the patient inappropriate for the study. Hypersensitivity to fluorescein sodium for injection, the investigational drug (danicopan) or any of its excipients. Note: Additional inclusion/exclusion criteria may apply, per protocol.
Facility Information:
Facility Name
Clinical Study Site
City
Phoenix
State/Province
Arizona
ZIP/Postal Code
85020
Country
United States
Facility Name
Clinical Study Site
City
Beverly Hills
State/Province
California
ZIP/Postal Code
90211
Country
United States
Facility Name
Clinical Study Site
City
Encino
State/Province
California
ZIP/Postal Code
91436
Country
United States
Facility Name
Clinical Study Site
City
Fresno
State/Province
California
ZIP/Postal Code
93720
Country
United States
Facility Name
Clinical Study Site
City
Fullerton
State/Province
California
ZIP/Postal Code
92835
Country
United States
Facility Name
Clinical Study Site
City
La Jolla
State/Province
California
ZIP/Postal Code
92093
Country
United States
Facility Name
Clinical Study Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Facility Name
Clinical Study Site
City
Mountain View
State/Province
California
ZIP/Postal Code
94040
Country
United States
Facility Name
Clinical Study Site
City
Pasadena
State/Province
California
ZIP/Postal Code
91105
Country
United States
Facility Name
Clinical Study Site
City
Sacramento
State/Province
California
ZIP/Postal Code
95841
Country
United States
Facility Name
Clinical Study Site
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Clinical Study Site
City
Colorado Springs
State/Province
Colorado
ZIP/Postal Code
80909
Country
United States
Facility Name
Clinical Study Site
City
Longmont
State/Province
Colorado
ZIP/Postal Code
50266
Country
United States
Facility Name
Clinical Study Site
City
Waterford
State/Province
Connecticut
ZIP/Postal Code
06385
Country
United States
Facility Name
Clinical Study Site
City
Clearwater
State/Province
Florida
ZIP/Postal Code
33761
Country
United States
Facility Name
Clinical Study Site
City
Coral Springs
State/Province
Florida
ZIP/Postal Code
33067
Country
United States
Facility Name
Clinical Study Site
City
Deerfield Beach
State/Province
Florida
ZIP/Postal Code
33064
Country
United States
Facility Name
Clinical Study Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32224
Country
United States
Facility Name
Clinical Study Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33136
Country
United States
Facility Name
Clinical Study Site
City
Miami
State/Province
Florida
ZIP/Postal Code
33143
Country
United States
Facility Name
Clinical Study Site
City
Naples
State/Province
Florida
ZIP/Postal Code
34103
Country
United States
Facility Name
Clinical Study Site
City
Palm Beach Gardens
State/Province
Florida
ZIP/Postal Code
33418
Country
United States
Facility Name
Clinical Study Site
City
Saint Petersburg
State/Province
Florida
ZIP/Postal Code
33711
Country
United States
Facility Name
Clinical Study Site
City
Augusta
State/Province
Georgia
ZIP/Postal Code
30909
Country
United States
Facility Name
Clinical Study Site
City
New Albany
State/Province
Indiana
ZIP/Postal Code
47150
Country
United States
Facility Name
Clinical Study Site
City
West Des Moines
State/Province
Iowa
ZIP/Postal Code
50266
Country
United States
Facility Name
Clinical Study Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21204
Country
United States
Facility Name
Clinical Study Site
City
Baltimore
State/Province
Maryland
ZIP/Postal Code
21237
Country
United States
Facility Name
Clinical Study Site
City
Hagerstown
State/Province
Maryland
ZIP/Postal Code
21740
Country
United States
Facility Name
Clinical Study Site
City
Springfield
State/Province
Massachusetts
ZIP/Postal Code
01107
Country
United States
Facility Name
Clinical Study Site
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55435
Country
United States
Facility Name
Clinical Study Site
City
Southaven
State/Province
Mississippi
ZIP/Postal Code
38671
Country
United States
Facility Name
Clinical Study Site
City
Reno
State/Province
Nevada
ZIP/Postal Code
89502
Country
United States
Facility Name
Clinical Study Site
City
Teaneck
State/Province
New Jersey
ZIP/Postal Code
07666
Country
United States
Facility Name
Clinical Study Site
City
Hauppauge
State/Province
New York
ZIP/Postal Code
11788
Country
United States
Facility Name
Clinical Study Site
City
Durham
State/Province
North Carolina
ZIP/Postal Code
27705
Country
United States
Facility Name
Clinical Study Site
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45219
Country
United States
Facility Name
Clinical Study Site
City
Cleveland
State/Province
Ohio
ZIP/Postal Code
44195
Country
United States
Facility Name
Clinical Study Site
City
Edmond
State/Province
Oklahoma
ZIP/Postal Code
73013
Country
United States
Facility Name
Clinical Study Site
City
Oklahoma City
State/Province
Oklahoma
ZIP/Postal Code
73104
Country
United States
Facility Name
Clinical Study Site
City
Eugene
State/Province
Oregon
ZIP/Postal Code
97401
Country
United States
Facility Name
Clinical Study Site
City
Portland
State/Province
Oregon
ZIP/Postal Code
97225
Country
United States
Facility Name
Clinical Study Site
City
Springfield
State/Province
Oregon
ZIP/Postal Code
97477
Country
United States
Facility Name
Clinical Study Site
City
Kingston
State/Province
Pennsylvania
ZIP/Postal Code
18704
Country
United States
Facility Name
Clinical Study Site
City
Monroeville
State/Province
Pennsylvania
ZIP/Postal Code
15146
Country
United States
Facility Name
Clinical Study Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104
Country
United States
Facility Name
Clinical Study Site
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19107
Country
United States
Facility Name
Clinical Study Site
City
Greenville
State/Province
South Carolina
ZIP/Postal Code
29605
Country
United States
Facility Name
Clinical Study Site
City
Ladson
State/Province
South Carolina
ZIP/Postal Code
29456
Country
United States
Facility Name
Clinical Study Site
City
Rapid City
State/Province
South Dakota
ZIP/Postal Code
57701
Country
United States
Facility Name
Clinical Study Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78705
Country
United States
Facility Name
Clinical Study Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78750
Country
United States
Facility Name
Clinical Study Site
City
Bellaire
State/Province
Texas
ZIP/Postal Code
77401
Country
United States
Facility Name
Clinical Study Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75231
Country
United States
Facility Name
Clinical Study Site
City
San Antonio
State/Province
Texas
ZIP/Postal Code
78240
Country
United States
Facility Name
Clinical Study Site
City
Southlake
State/Province
Texas
ZIP/Postal Code
76092
Country
United States
Facility Name
Clinical Study Site
City
The Woodlands
State/Province
Texas
ZIP/Postal Code
77384
Country
United States
Facility Name
Clinical Study Site
City
Fairfax
State/Province
Virginia
ZIP/Postal Code
22031
Country
United States
Facility Name
Clinical Study Site
City
Lynchburg
State/Province
Virginia
ZIP/Postal Code
24502
Country
United States
Facility Name
Clinical Study Site
City
Adelaide
ZIP/Postal Code
5000
Country
Australia
Facility Name
Clinical Study Site
City
Albury
ZIP/Postal Code
2640
Country
Australia
Facility Name
Clinical Study Site
City
Hurstville
ZIP/Postal Code
2220
Country
Australia
Facility Name
Clinical Study Site
City
Melbourne
ZIP/Postal Code
3002
Country
Australia
Facility Name
Clinical Study Site
City
Parramatta
ZIP/Postal Code
2150
Country
Australia
Facility Name
Clinical Study Site
City
Strathfield
ZIP/Postal Code
2135
Country
Australia
Facility Name
Clinical Study Site
City
Sydney
ZIP/Postal Code
2000
Country
Australia
Facility Name
Clinical Study Site
City
Ottawa
State/Province
Ontario
ZIP/Postal Code
K1H8L6
Country
Canada
Facility Name
Clinical Study Site
City
Pardubice
ZIP/Postal Code
53002
Country
Czechia
Facility Name
Clinical Study Site
City
Prague
ZIP/Postal Code
12808
Country
Czechia
Facility Name
Clinical Study Site
City
Praha
ZIP/Postal Code
15000
Country
Czechia
Facility Name
Clinical Study Site
City
Créteil
ZIP/Postal Code
94000
Country
France
Facility Name
Clinical Study Site
City
La Tronche
ZIP/Postal Code
38700
Country
France
Facility Name
Clinical Study Site
City
Lyon
ZIP/Postal Code
69004
Country
France
Facility Name
Clinical Study Site
City
Marseille
ZIP/Postal Code
13008
Country
France
Facility Name
Clinical Study Site
City
Nantes
ZIP/Postal Code
44000
Country
France
Facility Name
Clinical Study Site
City
Nice
ZIP/Postal Code
06000
Country
France
Facility Name
Clinical Study Site
City
Paris
ZIP/Postal Code
75010
Country
France
Facility Name
Clinical Study Site
City
Paris
ZIP/Postal Code
75019
Country
France
Facility Name
Clinical Study Site
City
Paris
ZIP/Postal Code
75571
Country
France
Facility Name
Clinical Study Site
City
Poitiers
ZIP/Postal Code
86021
Country
France
Facility Name
Clinical Study Site
City
Strasbourg
ZIP/Postal Code
67091
Country
France
Facility Name
Clinical Study Site
City
Écully
ZIP/Postal Code
69130
Country
France
Facility Name
Clinical Study Site
City
Berlin
ZIP/Postal Code
12203
Country
Germany
Facility Name
Clinical Study Site
City
Bonn
ZIP/Postal Code
53127
Country
Germany
Facility Name
Clinical Study Site
City
Düsseldorf
ZIP/Postal Code
40225
Country
Germany
Facility Name
Clinical Study Site
City
Freiburg
ZIP/Postal Code
79106
Country
Germany
Facility Name
Clinical Study Site
City
Göttingen
ZIP/Postal Code
37075
Country
Germany
Facility Name
Clinical Study Site
City
Hannover
ZIP/Postal Code
30625
Country
Germany
Facility Name
Clinical Study Site
City
Heidelberg
ZIP/Postal Code
69120
Country
Germany
Facility Name
Clinical Study Site
City
Mainz
ZIP/Postal Code
55131
Country
Germany
Facility Name
Clinical Study Site
City
Marburg
ZIP/Postal Code
35043
Country
Germany
Facility Name
Clinical Study Site
City
Munster
ZIP/Postal Code
48145
Country
Germany
Facility Name
Clinical Study Site
City
München
ZIP/Postal Code
81675
Country
Germany
Facility Name
Clinical Study Site
City
Münster
ZIP/Postal Code
48149
Country
Germany
Facility Name
Clinical Study Site
City
Neubrandenburg
ZIP/Postal Code
17036
Country
Germany
Facility Name
Clinical Study Site
City
Regensburg
ZIP/Postal Code
93053
Country
Germany
Facility Name
Clinical Study Site
City
Tübingen
ZIP/Postal Code
72076
Country
Germany
Facility Name
Clinical Study Site
City
Ulm
ZIP/Postal Code
89081
Country
Germany
Facility Name
Clinical Study Site
City
Würzburg
ZIP/Postal Code
97080
Country
Germany
Facility Name
Clinical Study Site
City
Budapest
ZIP/Postal Code
1133
Country
Hungary
Facility Name
Clinical Study Site
City
Pécs
ZIP/Postal Code
7621
Country
Hungary
Facility Name
Clinical Study Site
City
Firenze
ZIP/Postal Code
50134
Country
Italy
Facility Name
Clinical Study Site
City
Genova
ZIP/Postal Code
16132
Country
Italy
Facility Name
Clinical Study Site
City
Milano
ZIP/Postal Code
20122
Country
Italy
Facility Name
Clinical Study Site
City
Milano
ZIP/Postal Code
20132
Country
Italy
Facility Name
Clinical Study Site
City
Milan
ZIP/Postal Code
20157
Country
Italy
Facility Name
Clinical Study Site
City
Naples
ZIP/Postal Code
80131
Country
Italy
Facility Name
Clinical Study Site
City
Rome
ZIP/Postal Code
00133
Country
Italy
Facility Name
Clinical Study Site
City
Rome
ZIP/Postal Code
00168
Country
Italy
Facility Name
Clinical Study Site
City
Kita-Gun
State/Province
Kida-gun, Kagawa
ZIP/Postal Code
761-0793
Country
Japan
Facility Name
Clinical Study Site
City
Fukushima-shi
ZIP/Postal Code
960-1295
Country
Japan
Facility Name
Clinical Study Site
City
Hirakata-Shi
ZIP/Postal Code
573-1191
Country
Japan
Facility Name
Clinical Study Site
City
Nagoya
ZIP/Postal Code
467-8602
Country
Japan
Facility Name
Clinical Study Site
City
Osaka-shi
ZIP/Postal Code
545-8586
Country
Japan
Facility Name
Clinical Study Site
City
Busan
ZIP/Postal Code
49241
Country
Korea, Republic of
Facility Name
Clinical Study Site
City
Daegu
ZIP/Postal Code
42415
Country
Korea, Republic of
Facility Name
Clinical Study Site
City
Incheon
ZIP/Postal Code
22332
Country
Korea, Republic of
Facility Name
Clinical Study Site
City
Jinju-si
ZIP/Postal Code
52727
Country
Korea, Republic of
Facility Name
Clinical Study Site
City
Seoul
ZIP/Postal Code
03080
Country
Korea, Republic of
Facility Name
Clinical Study Site
City
Seoul
ZIP/Postal Code
06351
Country
Korea, Republic of
Facility Name
Clinical Study Site
City
Riga
ZIP/Postal Code
1002
Country
Latvia
Facility Name
Clinical Study Site
City
Riga
ZIP/Postal Code
1009
Country
Latvia
Facility Name
Clinical Study Site
City
Bratislava
ZIP/Postal Code
81108
Country
Slovakia
Facility Name
Clinical Study Site
City
Žilina
ZIP/Postal Code
01207
Country
Slovakia
Facility Name
Clinical Study Site
City
Barcelona
ZIP/Postal Code
08022
Country
Spain
Facility Name
Clinical Study Site
City
Barcelona
ZIP/Postal Code
08035
Country
Spain
Facility Name
Clinical Study Site
City
Barcelona
ZIP/Postal Code
8025
Country
Spain
Facility Name
Clinical Study Site
City
Bilbao
ZIP/Postal Code
48006
Country
Spain
Facility Name
Clinical Study Site
City
Cordoba
ZIP/Postal Code
14012
Country
Spain
Facility Name
Clinical Study Site
City
Majadahonda
ZIP/Postal Code
28222
Country
Spain
Facility Name
Clinical Study Site
City
Pamplona
ZIP/Postal Code
31008
Country
Spain
Facility Name
Clinical Study Site
City
Seville
ZIP/Postal Code
41071
Country
Spain
Facility Name
Clinical Study Site
City
Valencia
ZIP/Postal Code
46014
Country
Spain
Facility Name
Clinical Study Site
City
Valladolid
ZIP/Postal Code
46012
Country
Spain
Facility Name
Clinical Study Site
City
Zaragoza
ZIP/Postal Code
50009
Country
Spain
Facility Name
Clinical Study Site
City
Bristol
ZIP/Postal Code
BS12LX
Country
United Kingdom
Facility Name
Clinical Study Site
City
Frimley
ZIP/Postal Code
GU167UJ
Country
United Kingdom
Facility Name
Clinical Study Site
City
Liverpool
ZIP/Postal Code
L693BX
Country
United Kingdom
Facility Name
Clinical Study Site
City
London
ZIP/Postal Code
EC1V2PD
Country
United Kingdom
Facility Name
Clinical Study Site
City
London
ZIP/Postal Code
NW15QH
Country
United Kingdom
Facility Name
Clinical Study Site
City
London
ZIP/Postal Code
SE59RS
Country
United Kingdom
Facility Name
Clinical Study Site
City
Newcastle Upon Tyne
ZIP/Postal Code
NE77DN
Country
United Kingdom
Facility Name
Clinical Study Site
City
Southampton
ZIP/Postal Code
S0166YD
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

We'll reach out to this number within 24 hrs